KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBITDA Margin (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of EBITDA Margin data on record, last reported at 268.63% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 12627.0% year-over-year to 268.63%; the TTM value through Sep 2025 reached 28.63%, down 8512.0%, while the annual FY2024 figure was 25.43%, 3894.0% up from the prior year.
  • EBITDA Margin reached 268.63% in Q3 2025 per NKTR's latest filing, up from 324.21% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1121.78% in Q4 2022 and bottomed at 708.07% in Q2 2022.
  • Average EBITDA Margin over 5 years is 118.35%, with a median of 246.84% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 136481bps in 2021, then tumbled -40099bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 892.89% in 2021, then grew by 26bps to 1121.78% in 2022, then plummeted by -36bps to 720.79% in 2023, then crashed by -55bps to 323.96% in 2024, then tumbled by -183bps to 268.63% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 268.63% in Q3 2025, 324.21% in Q2 2025, and 425.76% in Q1 2025.